1. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue.

    Cancer Letters 246(1-2):253 (2007) PMID 16624485

    We examined the methylation status of the Ep-CAM promoter region of human breast cancer cell lines and breast cancer tissue using MethyLight technology and bisulfite sequencing. We found the promoter of Ep-CAM-negative breast cancer cell lines Hs 578T to be methylated to a higher degree as compa...
  2. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue

    Cancer Letters 246(1):253 (2007)

    We examined the methylation status of the Ep-CAM promoter region of human breast cancer cell lines and breast cancer tissue using MethyLight technology and bisulfite sequencing. We found the promoter of Ep-CAM-negative breast cancer cell lines Hs 578T to be methylated to a higher degree as ...
  3. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer.

    Cancer Research 66(1):29 (2006) PMID 16397211

    The HER-2/neu gene is amplified and overexpressed in 20% to 30% of invasive breast carcinomas and is associated with increased metastatic potential and less tamoxifen sensitivity. We generated the DNA methylation profiles of 143 human breast tumors and found significant differences in HER-2/neu ...
  4. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients.

    Cancer Research 65(4):1141 (2005) PMID 15734995

    Adjuvant systemic therapy (a strategy that targets potential disseminated tumor cells after complete removal of the tumor) has clearly improved survival of patients with cancer. To date, no tool is available to monitor efficacy of these therapies, unless distant metastases arise, a situation tha...
  5. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool.

    Clinical Chemistry 50(11):2171 (2004) PMID 15502091